Abstract
In the third decade of the Helicobacter pylori era several informations are available on its pathogenetic mechanisms, as well as on therapeutic approaches. A 7-14 day triple or quadruple regimens (proton pump inhibitor together with 2 antibiotics) are currently suggested as first-line treatment, but the success rate following these therapy is constantly decreasing worldwide. Therefore, new drugs are needed to treat such a widespread infection. Several patents of new antibiotics have been claimed in the last 5 years, and some of them showed a very powerful antibacterial activity in vitro, even against clarithromycin and metronidazole resistant strains. Among the new compounds, thienylthiazole derivatives, benzamide derivatives and pyloricidins should be regarded as very promising molecules.
Keywords: Antibiotics, Helicobacter pylori, therapy
Recent Patents on Anti-Infective Drug Discovery
Title: Antibiotic Treatment Strategies for Helicobacter pylori Infection
Volume: 2 Issue: 1
Author(s): S.M. A. Campo, A. Zullo, C. Hassan and S. Morini
Affiliation:
Keywords: Antibiotics, Helicobacter pylori, therapy
Abstract: In the third decade of the Helicobacter pylori era several informations are available on its pathogenetic mechanisms, as well as on therapeutic approaches. A 7-14 day triple or quadruple regimens (proton pump inhibitor together with 2 antibiotics) are currently suggested as first-line treatment, but the success rate following these therapy is constantly decreasing worldwide. Therefore, new drugs are needed to treat such a widespread infection. Several patents of new antibiotics have been claimed in the last 5 years, and some of them showed a very powerful antibacterial activity in vitro, even against clarithromycin and metronidazole resistant strains. Among the new compounds, thienylthiazole derivatives, benzamide derivatives and pyloricidins should be regarded as very promising molecules.
Export Options
About this article
Cite this article as:
Campo A. S.M., Zullo A., Hassan C. and Morini S., Antibiotic Treatment Strategies for Helicobacter pylori Infection, Recent Patents on Anti-Infective Drug Discovery 2007; 2 (1) . https://dx.doi.org/10.2174/157489107779561706
DOI https://dx.doi.org/10.2174/157489107779561706 |
Print ISSN 1574-891X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4071 |
Related Articles
-
Guggulsterone for Chemoprevention of Cancer
Current Pharmaceutical Design Regeneration of Pancreatic β-Cells in vivo as a Potential Therapeutic Approach for Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Targeting EZH2 for Cancer Therapy: Progress and Perspective
Current Protein & Peptide Science Protein Biomarkers in Cancers of the Digestive Tract - a Step Towards Personalized Medicine
Current Proteomics Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non – small Cell Lung Cancer
Current Cancer Drug Targets Risk-Benefit Perspectives in COX-2 Blockade
Current Drug Safety Multiple-Target Drugs: Inhibitors of Heat Shock Protein 90 and of Histone Deacetylase
Current Drug Targets Clinical Development of Microbicides for the Prevention of HIV Infection
Current Pharmaceutical Design The GABAergic System and the Gastrointestinal Physiopathology
Current Pharmaceutical Design Molecular Mechanisms of Biological Activity of Oleanolic Acid - A Source of Inspiration for A New Drugs Design
Mini-Reviews in Organic Chemistry Subject Index
Current Drug Targets - Inflammation & Allergy Targeting Farnesoid-X-Receptor: From Medicinal Chemistry to Disease Treatment
Current Medicinal Chemistry Insight into p95HER2 in Breast Cancer: Molecular Mechanisms and Targeted Therapies
Recent Patents on DNA & Gene Sequences The Effect of Psychological Stress and Social Isolation on Neuroimmunoendocrine Communication
Current Pharmaceutical Design Fabrication, Optimization and Characterization of Paclitaxel and Spirulina Loaded Nanoparticles for Enhanced Oral Bioavailability
Current Nanoscience Trichostatin A - like Hydroxamate Histone Deacetylase Inhibitors as Therapeutic Agents: Toxicological Point of View
Current Medicinal Chemistry How to Make a Non-Antigenic Protein (Auto) Antigenic: Molecular Complementarity Alters Antigen Processing and Activates Adaptive-Innate Immunity Synergy
Anti-Cancer Agents in Medicinal Chemistry Seeds as a Production System for Molecular Pharming Applications: Status and Prospects
Current Pharmaceutical Design Clinical Management of Diabetes Mellitus in the Older Adult Patient
Current Diabetes Reviews BPC157 as Potential Agent Rescuing from Cancer Cachexia
Current Pharmaceutical Design